What is LLS?
The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. Founded in 1949, LLS is relentless in pursuit of their mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS was founded in 1949 and has 63 chapters nationwide.
Blood cancer research can be the gateway to curing other cancers. Since its inception in 1949, The Leukemia & Lymphoma Society has invested more than $680 million in research to find the cause and cure for blood cancers. This research has led to groundbreaking treatments – such as chemotherapy, radiation and stem cell transplantation – that are vital to treating both blood cancers as well as many other forms of cancer.
The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. Founded in 1949, LLS is relentless in pursuit of their mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS was founded in 1949 and has 63 chapters nationwide.
Blood cancer research can be the gateway to curing other cancers. Since its inception in 1949, The Leukemia & Lymphoma Society has invested more than $680 million in research to find the cause and cure for blood cancers. This research has led to groundbreaking treatments – such as chemotherapy, radiation and stem cell transplantation – that are vital to treating both blood cancers as well as many other forms of cancer.
What They Do
- Invest in blood cancer research: LLS has invested more than $814 million in research, over $76.6 million in fiscal year 2011 alone. Research funded by LLS has led or contributed to such advances as chemotherapy, bone marrow and stem cell transplantation and new, targeted oral therapies such as Gleevec®, Rituxin®, Velcade®, Thalidomid®, Revlimid®, Dacogen®, and Vidaza®.
- Provide critical information and support for patients and their families: LLS made 7.1 million contacts with patients, caregivers and healthcare professionals in fiscal year 2011 through their Information Resource Center (IRC), award-winning Web site and community-based patient services programs.
- Advocate for issues impacting blood cancer patients: With more than 56,000 advocates throughout the country, the LLS voice is being heard by those responsible for legislation to fund blood cancer research and educational programs.
Why They Do It
The need is critical: An estimated 1,012,533 people in the United States are living with, or are in remission from, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma or myeloma. Approximately every four minutes, someone new is diagnosed with blood cancer. Approximately every 10 minutes, someone dies. Leukemia causes more deaths than any other cancer among children, adolescents and young adults under the age of 20. Lymphomas are the most common blood cancers and incidence increases with age, and the survival rate for myeloma is only 41.1 percent
- Invest in blood cancer research: LLS has invested more than $814 million in research, over $76.6 million in fiscal year 2011 alone. Research funded by LLS has led or contributed to such advances as chemotherapy, bone marrow and stem cell transplantation and new, targeted oral therapies such as Gleevec®, Rituxin®, Velcade®, Thalidomid®, Revlimid®, Dacogen®, and Vidaza®.
- Provide critical information and support for patients and their families: LLS made 7.1 million contacts with patients, caregivers and healthcare professionals in fiscal year 2011 through their Information Resource Center (IRC), award-winning Web site and community-based patient services programs.
- Advocate for issues impacting blood cancer patients: With more than 56,000 advocates throughout the country, the LLS voice is being heard by those responsible for legislation to fund blood cancer research and educational programs.
Why They Do It
The need is critical: An estimated 1,012,533 people in the United States are living with, or are in remission from, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma or myeloma. Approximately every four minutes, someone new is diagnosed with blood cancer. Approximately every 10 minutes, someone dies. Leukemia causes more deaths than any other cancer among children, adolescents and young adults under the age of 20. Lymphomas are the most common blood cancers and incidence increases with age, and the survival rate for myeloma is only 41.1 percent
